Valneva announces resumption of trading of its ordinary shares on Euronext Paris

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announces the resumption of trading of its ordinary shares on the regulated market of Euronext in Paris, starting at 4:30pm CEST today.

At the request of the Company, trading of Valneva’s ordinary shares was suspended on June 23, 2022 from 9:00 AM CEST to allow for the publication of a press release by the European Medicines Agency regarding the Committee for Medicinal Products for Human Use (CHMP) opinion on marketing authorization in Europe for Valneva’s COVID-19 vaccine candidate, VLA2001.

About Valneva SE

Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing these diseases. Valneva has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)